[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-337356-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-337356-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","early-tumor-shrinkage-and-depth-of-response-as-predictors-of-survival-for-advanced-biliary-tract-cancer-an-exploratory-analysis-of-jcog1113","Early Tumor Shrinkage and Depth of Response as Predictors of Survival for Advanced Biliary Tract Cancer - An Exploratory Analysis of JCOG1113","","Background: Recent studies indicate early tumor shrinkage (ETS) and depth of response (DpR) may reflect chemotherapy outcomes across cancers. This exploratory analysis assessed the association of ETS and DpR with clinical outcomes in chemotherapy-naïve advanced biliary tract cancer using JCOG1113, which previously showed gemcitabine plus S-1 (GS) non-inferior to gemcitabine plus cisplatin (GC). Material and methods: 354 patients were stratified by ETS at week 6 and DpR up to 12 weeks; survival effects were evaluated with multivariable Cox models.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/early-tumor-shrinkage-and-depth-of-response-as-predictors-of-survival-for-advanced-biliary-tract-cancer-an-exploratory-analysis-of-jcog1113/337356/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/early-tumor-shrinkage-and-depth-of-response-as-predictors-of-survival-for-advanced-biliary-tract-cancer-an-exploratory-analysis-of-jcog1113/337356.png","ImageObject",300,407,{"name":42,"@type":43},"Jiven","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-15","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",12,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What are ETS and DpR in this analysis?","Question",{"text":63,"@type":64},"ETS (early tumor shrinkage) reflects tumor reduction at week 6, and DpR (depth of response) reflects the maximum tumor shrinkage achieved up to 12 weeks. They are evaluated as on-treatment markers of outcome.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How were patients grouped for ETS and DpR?",{"text":68,"@type":64},"Patients with measurable target lesions were divided into ETS-unachieved versus ETS-achieved groups (≥20% reduction at week 6) and DpR-low versus DpR-high groups (≥40% maximum shrinkage up to 12 weeks).",{"name":70,"@type":61,"acceptedAnswer":71},"What outcomes were associated with ETS and DpR?",{"text":72,"@type":64},"In multivariable analyses, ETS-achieved and DpR-high groups showed hazard ratios indicating improved progression-free survival (PFS) and overall survival (OS). The GC arm also showed limited progression after the landmark for many ETS-achieved patients.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},337356,1790145750,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":140,"language":141,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":12,"update_tm":145,"read_time":146,"preview_page_count":33,"preview_urls":147},1099513958607,"https://ap-avatar.wpscdn.com/avatar/100002390cf8733938c?x-image-process=image/resize,m_fixed,w_180,h_180&k=1778829742770036399","Early Tumor Shrinkage and Depth of Response as Predictors of Survival for Advanced Biliary Tract Cancer: An Exploratory Analysis of JCOG1113  \nNaohiro Okano*, 1,, Chigusa Morizane2,, Takuji Okusaka2, Ryo Sadachi3, Tomoko Kataoka3, Satoshi Kobayashi4,, Masafumi Ikeda5,, Masato Ozaka6, Tomonori Mizutani1,,  \nKazuya Sugimori7, Akiko Todaka8,, Satoshi Shimizu9,, Nobumasa Mizuno10,,  \nTomohisa Yamamoto11, Keiji Sano12, Kazutoshi Tobimatsu13, Akio Katanuma14, Kunihito Gotoh15, Hironori Yamaguchi16, Hiroshi Ishii17, Akihiro Ohba2, Junji Furuse1,4, Makoto Ueno4, Hepatobiliary and Pancreatic Oncology Group of Japan Clinical Oncology Group (JCOG)  \n1Department of Medical Oncology, Kyorin University Faculty of Medicine, Tokyo, Japan  \n2Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Tokyo, Japan 3JCOG Data Center/Operations Office, National Cancer Center Hospital, Tokyo, Japan  \n4Department of Gastroenterology, Kanagawa Cancer Center, Yokohama, Japan  \n5Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, Kashiwa, Japan 6 Hepato-Biliary-Pancreatic Medicine Department, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan  \n7Gastroenterological Center, Yokohama City University Medical Center, Yokohama, Japan 8Division of Gastrointestinal Oncology, Shizuoka Cancer Center, Shizuoka, Japan 9Department of Gastroenterology, Saitama Cancer Center, Saitama, Japan 10Department of Gastroenterology, Aichi Cancer Center Hospital, Nagoya, Japan 11Department of Surgery, Kansai Medical University Hospital, Osaka, Japan 12Department of Surgery, Teikyo University School of Medicine, Tokyo, Japan  \n13Division of Gastroenterology, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe, Japan 14Center for Gastroenterology, Teine Keijinkai Hospital, Sapporo, Japan  \n15Department of Surgery, National Hospital Organization Osaka National Hospital, Osaka, Japan 16Department of Clinical Oncology, Jichi Medical University, Tochigi, Japan  \n17Clinical Research Center, Chiba Cancer Center, Chiba, Japan  \n*Corresponding author: Naohiro Okano, MD, PhD, Department of Medical Oncology, Kyorin University Faculty of Medicine, 6-20-2, Shinkawa, Mitaka-shi, Tokyo 181-8611, Japan. Tel: +81 422 47 5511; Fax: +81 422 44 0729; E-mail: [naohiro-okano@ks.kyorin-u.ac.jp](naohiro-okano@ks.kyorin-u.ac.jp)  \nAbstract  \nBackground: Recent studies suggest that early tumor shrinkage (ETS) and depth of response (DpR) reflect outcomes of chemotherapy in various cancers . This study evaluated the association of ETS and DpR with clinical outcomes using data from JCOG1113, which demonstrated the non-inferiority of gemcitabine plus S-1 (GS) to gemcitabine plus cisplatin (GC) for chemotherapy-naïve advanced biliary tract cancer.  \nMaterial and Methods: In total, 354 (289 with measurable target lesions) patients enrolled in JCOG1113 were divided into ETS-unachieved and ETS-achieved groups (≥20% tumor reduction at week 6) and DpR-low and DpR-high groups (≥40% maximum shrinkage) until 12 weeks after enrollment. The impact of ETS and DpR on survival outcome was evaluated using the multivariable Cox proportional hazard model.  \nResults: The proportions of patients in the ETS-achieved and DpR-high groups were similar between the 2 treatment arms. The hazard ratios (HRs) of progression-free survival (PFS) and overall survival (OS) for the ETS-achieved group were 0.70 (95% confidence interval (CI), 0.52-0.93) and 0.60 (95%CI, 0.44-0.81), respectively. The HRs of PFS and OS for the DpR-high group were 0.67 (95%CI, 0.48-0.94) and 0.64 (95%CI, 0.46- 0.90), respectively. In the subpopulation treatment effect pattern plot analysis, most patients in the ETS-achieved group in the GC arm did not experience disease progression after 12 weeks from the landmark.  \nConclusion: As on-treatment markers, ETS and DpR were effective tools. ETS was clinically useful, because it can be us","cbCaijwviwdeIMTY","https://ap.wps.com/l/cbCaijwviwdeIMTY","pdf",2182269,11,"English","# Abstract\n## Background\n## Material and Methods\n## Results\n## Conclusion\n# Implications for Practice\n# Introduction","[{\"question\":\"What are ETS and DpR in this analysis?\",\"answer\":\"ETS (early tumor shrinkage) reflects tumor reduction at week 6, and DpR (depth of response) reflects the maximum tumor shrinkage achieved up to 12 weeks. They are evaluated as on-treatment markers of outcome.\"},{\"question\":\"How were patients grouped for ETS and DpR?\",\"answer\":\"Patients with measurable target lesions were divided into ETS-unachieved versus ETS-achieved groups (≥20% reduction at week 6) and DpR-low versus DpR-high groups (≥40% maximum shrinkage up to 12 weeks).\"},{\"question\":\"What outcomes were associated with ETS and DpR?\",\"answer\":\"In multivariable analyses, ETS-achieved and DpR-high groups showed hazard ratios indicating improved progression-free survival (PFS) and overall survival (OS). The GC arm also showed limited progression after the landmark for many ETS-achieved patients.\"}]","Early Tumor Shrinkage and Depth of Response as Predictors of Survival for Advanced Biliary Tract Cancer - An Exploratory Analysis of JCOG1113 | PDF",1790018747,28,[148,152,156,160],{"page_no":22,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2d44da1431ec827ce55bdf0e76041152.webp",983,1291,{"page_no":26,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3e729b0a199a9f85178d76bac3563992.webp",982,1290,{"page_no":30,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7e2fd55ff4bb083b93b15ed89361ad42.webp",981,1289,{"page_no":33,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/19c2e627dae4038ce371776ef07f9262.webp",980,1287]